Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications

Medicinal Research Reviews

Volumn 23, Issue 4, 2003, Pages 393-426

  Romanelli, M Novella ^a   Gualtieri, Fulvio ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allosteric modulators; Competitive ligands; Nicotinic receptors; Subtype selectivity

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; A 84543; ANATOXIN; ARECOLINE; AZANICOTINE; BUNGAROTOXIN; CHROMAN DERIVATIVE; CYTISINE; EPIBATIDINE; EPIBATIDINE DERIVATIVE; EPIBOXIDINE; HOMOAZANICOTINE; IMIDACLOPRID; LOBELINE; LOPHOTOXIN; MEMBRANE PROTEIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NNC 90 0270; PHILANTHOTOXIN; QUINUCLIDINE DERIVATIVE; RECEPTOR SUBTYPE; TUBOCURARINE CHLORIDE; UB 165; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; BINDING AFFINITY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NONHUMAN; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BINDING SITES; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, CHOLINERGIC; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC;

EID: 0038469953     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10037     Document Type: Review

References (281)

1. Dale HH. The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914;6:147-190.
2. Dale HH. The beginning and the prospects of neuro-humoral transmission. Pharmacol Rev 1954;4:7-13.
3. Paton WDM, Zaimis EJ. The methonium compounds. Pharmacol Rev 1952;4:219-253.
4. Goodman A, Gilman A. The Pharmacological Basis of Therapeutics. VIIth edition. New York: Macmillan Publishing Company; 1985.
5. Clarke PBS. Recent progress in identifying nicotinic cholinoceptors in mammalian brain. Trends Pharmacol Sci 1987;8:32-35.
6. Lloyd GK, Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 2000;292:461-467.
7. Galzi JL, Devillers-Thiery A, Hussy N, Bertrand S, Changeux J-P, Bertrand D. Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. Nature 1992;359:500-505.
8. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux J-P, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 1993;366:479-483.
9. 3 receptor subunit. J Biol Chem 1999;274:3934-3936.
10. Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998;18:2954-2961.
11. 3 receptors form stable trimers: A novel structural motif of ligand-gated ion channels. EMBO J 1998;17:3016-3028.
12. Hucho F, Weise C. Ligand-gated ion channels. Angew Chem Int Ed 2001;40:3100-3116.
13. Lukas RJ. Diversity and pattern regulation of nicotinic receptor subtypes. In: Diversity of interacting receptors. New York: 1995. pp 153-168.
14. Unwin N. The nicotinic acetylcholine receptor of Torpedo electric ray. J Struct Biol 1998;121:181-190.
15. Hucho F. The nicotinic acetylcholine receptor and its ion channel. Eur J Biochem 1986;158:211-226.
16. Unwin N, Toyoshima C, Kubalek E. Arrangement of the acetylcholine receptor subunits in the resting and the desensitized states, determined by cryoelectron microscopy of crystallized Torpedo postsynaptic membranes. J Cell Biol 1988;107:1123-1138.
17. Gorne-Tschelnokow U, Strecker A, Kaduk C, Naumann D, Hucho F. The transmembrane domains of the nicotinic acetylcholine receptor contain alpha-helical and beta structures. EMBO J 1994;13:338-341.
18. Swope SL, Moss SJ, Blackstone CD, Huganir RL. Phosphorylation of ligand-gated ion channels: A possible mode of synaptic plasticity. FASEB J 1992;6:2514-2523.
19. Levitan IB. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol 1994;56:193-212.
20. Utkin YN, Tsetlin VI, Hucho F. Structural organization of nicotinic acetylcholine receptors. Membr Cell Biol 2000;13:143-164.
21. Methot N, Ritchie BD, Blanton MP, Baenziger JE. Structure of the pore-forming transmembrane domain of a ligand-gated ion channel. J Biol Chem 2001;276:23726-23732.
22. Le Novère N, Corringer P-J, Changeux J-P. Improved secondary structure predictions for a nicotinic receptor subunit: Incorporation of solvent accessibility and experimental data into a two-dimensional representation. Biophys J 1999;76:2329-2345.
23. Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995;373:37-43.
24. Akabas MH, Karlin A. Identification of acetylcholine receptor channel-lining residues in the M1 segment of the alpha-subunit. Biochemistry 1995;34:12496-12500.
25. Zhang H, Karlin A. Identification of acetylcholine receptor channel-lining residues in the M1 segment of the β subunit. Biochemistry 1997;36:15856-15864.
26. Imoto K. Molecular aspect of ion permeation through channels. Ann NY Acad Sci 1993;707:38-50.
27. Corringer P-J, Le Novère N, Changeux J-P. Nicotinic receptors at the aminoacid level. Annu Rev Pharmacol Toxicol 2000;40:431-458.
28. Itier V, Bertrand D. Neuronal nicotinic receptors: From protein structure to function. FEBS Lett 2001;504:118-125.
29. Palma E, Bertrand S, Binzoni T, Bertrand D. Neuronal nicotinic α receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 1996;491:151-161.
30. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411:269-276.
31. Valenzuela CF, Weign P, Yguerabide J, Johnson DA. Transverse distance between the membrane and the agonist binding sites on the Torpedo acetylcholine receptor: A fluorescence study. Biophys J 1994;66:674-682.
32. Miyazawa A, Fujiyoshi Y, Stowell M, Unwin N. Nicotinic acetylcholine receptor at 4.6 Å resolution: Transverse tunnels in the channel wall. J Mol Biol 1999;288:765-786.
33. Arias HR. Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem Int 2000;36:595-645.
34. Clementi F, Fornasari D, Gotti C. Neuronal nicotinic receptors, important new players in brain function. Eur J Pharmacol 2000;393:3-10.
35. Arneric SP, Sullivan JP, Williams M. Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995. pp 94-110.
36. MacDermott AB, Role LW, Siegelbaum SA. Presynaptic ionotropic receptors and the control of neurotransmitter release. Ann Rev Neurosci 1999;22:443-485.
37. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: Correlating physiology with function. Trends Neurosci 1999;22:555-561.
38. Cordero-Erausquin M, Marubio LM, Klink R, Changeux J-P. Nicotinic receptor function: New perspective from knockout mice. Trends Pharmacol Sci 2000;21:211-217.
39. Marubio LM, Changeux J-P. Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function. Eur J Pharmacol 2000;393:113-121.
40. Lukas RJ, Changeux J-P, Le Novère N, Albuquerque EX, Balfour DJK, Berg DK, Bertrand D, Chiappinelli VA, Clarke PBS, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom J, Marks MJ, Quik M, Taylor PW, Wonnacott S. International union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401.
41. Zoli M, Léna C, Picciotto MR, Changeux J-P. Identification of four classes of brain nicotinic receptors using β2 mutant mice. J Neurosci 1998;18:4461-4472.
42. Sgard F, Charpantier E, Bertrand S, Walker N, Caput D, Graham D, Bertrand D, Besnard F. A novel human nicotinic receptor subunit, α10, that confers functionality to the α9-subunit. Mol Pharmacol 2002;61:150-159.
43. Colquhoun LM, Patrick JW. α3, β2, and β4 form heterotrimeric receptors in Xenopus oocytes. J Neurochem 1997;69:2355-2362.
44. Conroy WG, Vernallis AB, Berg DK. The α5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron 1992;679-691.
45. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J. Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J Biol Chem 1996;271:17656-17665.
46. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, Yakel JL. Rat nicotinic ACh receptor α7 and β2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002;540:425-434.
47. Alkondon M, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther 1993;265:1455-1473.
48. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997;53:199-237.
49. Lukas RJ. Cell lines as models for studies of nicotinc acetylcholine receptors. In: Arneric SP, Brioni JD, editors. Neuronal nicotinic receptors: Pharmacology and therapeutic opportunities. New York: Wiley-Liss; 1998. pp 81-97.
50. Truong A, Xing X, Forsayeth JR, Dwoskin LP, Crooks PA, Cohen BN. Pharmacological differences between immunoisolated native brain and heterologously expressed rat α4β2 nicotinic receptors. Mol Brain Res 2001;96:68-76.
51. Lewis TM, Harkness PC, Sivilotti LG, Colquhoun D, Millar NS. The ion channel properties of a rat recombinant neuronal nicotinic receptor are dependent on the host cell type. J Physiol 1997;505:299-306.
52. Nelson ME, Linstrom J. Single channel properties of human α3 AChRs: Impact of β2, β4, and α5 subunits. J Physiol 1999;516:657-678.
53. Sivilotti LG, McNeil DK, Lewis TM, Nassar MA, Schoepfer R, Colquhoun D. Recombinant nicotinic receptors, expressed in Xenopus oocytes, do not resemble native rat sympathetic ganglion receptors in single-channel behavior. J Physiol 1997;500:123-138.
54. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 1997;40:4169-4194.
55. Imming P, Klaperski P, Stubbs MT, Seitz G, Gündisch D. Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands. Eur J Med Chem 2001;36:375-388.
56. Parker MJ, Beck A, Luetje CW. Neuronal nicotinic receptor β2 and β4 subunits confer large differences in agonist binding affinity. Mol Pharmacol 1998;54:1132-1139.
57. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King SL, Picciotto MR, Innis RB, London ED. 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000;57:642-649.
58. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Holladay MW, Williams M, Arneric SP. A-85380 [3-[2(S)-azetidinylmethoxy)pyridine]: In vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996;35:725-734.
59. Kulak JM, Sum J, Musachio JL, McIntosh JM, Quik M. 5-Iodo-A-85380 binds to α-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as α4β2* subtypes. J Neurochem 2002;81:403-406.
60. McIntosh JM, Santos AD, Olivera BM. Conus peptides targeted to specific nicotinic acetylcoline receptor subtypes. Annu Rev Biochem 1999;65:59-88.
61. Johnson DS, Martinez J, Elgoyhen AB, Heinemann SS, McIntosh JM. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: Preferential inhibition of homomeric alpha 7 and alpha 9 receptors. Mol Pharmacol 1995;48:194-199.
62. Pereira EF, Alkondon M, McIntosh JM, Albuquerque EX. Alpha-conotoxin-ImI: A competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons. J Pharmacol Exp Ther 1996;278:1472-1483.
63. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. J Biol Chem 1996;271:7522-7528.
64. Champtiaux N, Han Z-Y, Bessis A, Rossi FM, Zoli M, Marubio L, McIntosh JM, Changeux J-P. Distribution and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 2002;22:1208-1217.
65. Holladay MW, Lebold SA, Lin N-H. Structure-activity relationships of nicotinic acetylcholine receptor agonists as potential treatments for dementia. Drug Dev Res 1995;35:191-213.
66. Schmitt JD, Bencherif M. Targeting nicotinic acetylcholine receptors: Advances in molecular design and therapies. Annu Rep Med Chem 2000;35:41-51.
67. Schmitt JD. Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr Med Chem 2000;7:749-800.
68. Dwoskin LP, Xu R, Ayers JY, Crooks PA. Recent developments in neuronal nicotinic acetylcholine receptor antagonists. Exp Opin Ther Patents 2000;10:1561-1581.
69. Tønder JE, Olesen PH. Agonists at the α4β2 nicotinic acetylcholine receptors: Structure-activity relationships and molecular modelling. Curr Med Chem 2001;8:651-674.
70. Ferretti G, Dukat M, Giannella M, Piergentili A, Pigini M, Quaglia W, Damaj MI, Martin BR, Glennon RA. Chain-lengthened and imidazoline analogues of nicotine. Bioorg Med Chem Lett 2000;10:2665-2668.
71. Silva NM, Tributino JLM, Miranda ALP, Barreiro EJ, Fraga CAM. New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. Eur J Med Chem 2002;37:163-170.
72. Guandalini L, Dei S, Manetti D, Romanelli MN, Scapecchi S, Teodori E, Varani K. Synthesis and pharmacological evaluation of some (pyridyl)cyclopropylmethyl amines and their methiodides as nicotinic receptor ligands. Il Farmaco 2002;57:487-496.
73. Xu R, Dwoskin LP, Grinevich VP, Deaciuc G, Crooks PA. Neuronal nicotinic acetylcholine receptor binding affinities of boron-containing nicotine analogues. Bioorg Med Chem Lett 2001;11:1245-1248.
74. Lin N-H, Gunn DE, Li Y, He Y, Bai H, Ryther KB, Kuntzweiler T, Donnelly-Roberts DL, Anderson DJ, Campbell JE, Sullivan JP, Arneric SP, Holladay MW. Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. Bioorg Med Chem Lett 1998;8:249-254.
75. Lin N-H, Li Y, He Y, Holladay MW, Kuntzweiler T, Anderson DJ, Campbell JE, Arneric SP. Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine A-84543: A potent nicotinic receptor ligand. Bioorg Med Chem Lett 2001;11:631-633.
76. Lin N-H, Abreo MA, Gunn DE, Lebold SA, Lee EL, Wasicak JT, Hettinger AM, Daanen JF, Garvey DS, Campbell JE, Sullivan JP, Williams M, Arneric SP. Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework. Bioorg Med Chem Lett 1999;9:2747-2752.
77. Lee J, Davis CB, Rivero RA, Reitz AB, Shank RP. Synthesis and structure-activity relationship of novel pyridyl ethers for the nicotinic acetylcholine receptor. Bioorg Med Chem Lett 2000;10:1063-1066.
78. Krow GR, Yuan J, Fang Y, Meyer MD, Anderson DJ, Campbell JE, Carroll PJ. Synthesis of 3- and 5-endo-(6-chloro-3-pyridoxy)-methyl-2-azabicyclo[2.2.0]hexane and 3-endo-(6-chloro-3-pyridoxy)-methyl-2-azabicyclo[2.2.0]hex-5-ene. ABT 594 analogs. Tetrahedron 2000;56:9227-9232.
79. Balboni G, Marastoni M, Merighi S, Borea PA, Tomatis R. Synthesis and binding of 3-aminopyridine derivatives at central nicotinic receptors. Arzneim-Forsch/Drug Res 2000;50:507-511.
80. Balboni G, Marastoni M, Merighi S, Borea PA, Tomatis R. Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors. Eur J Med Chem 2000;35:979-988.
81. Abreo MA, Lin N-H, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, Pavlik PA, Martin YC, Donnelly-Roberts DL, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem 1996;39:817-825.
82. Liang F, Navarro HA, Abraham P, Kotian P, Ding Y-S, Fowler J, Volkow N, Kuhar MJ, Carroll FI. Synthesis and nicotinic acetylcholine receptor binding properties of exo-2-(2′-fluoro-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane: A new positron emission tomography ligand for nicotinic receptors. J Med Chem 1997;40:2293-2295.
83. Carroll FI, Liang F, Navarro HA, Brieaddy LE, Abraham P, Damaj MI, Martin BR. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues. J Med Chem 2001;44:2229-2237.
84. Carroll FI, Lee JR, Navarro HA, Brieaddy LE, Abraham P, Damaj MI, Martin BR. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted-3′-phenyl-5′-pyridinyl)-7- azabicyclo[2.2.1]heptanes. Novel nicotinic antagonists. J Med Chem 2001;44:4039-4041.
85. Seerden J-PG, Tulp MTM, Scheeren HW, Kruse CG. Synthesis and structure-activity data of some new epibatidine analogues. Bioorg Med Chem 1998;6:2103-2110.
86. Badio B, Garraffo HM, Plummer CV, Padgett WL, Daly JW. Synthesis and nicotinic activity of epiboxidine: An isoxazole analogue of epibatidine. Eur J Pharmacol 1997;321:189-194.
87. Che D, Wegge T, Stubbs MT, Seitz G, Meier H, Methfessel C. exo 2-(Pyridazin-4-yl)-7-azabicyclo[2.2.1]-heptanes: Syntheses and nicotinic acetylcholine receptor agonist activity of potent pyridazine analogues of (±)-epibatidine. J Med Chem 2001;44:47-57.
88. Krow GR, Yuan J, Huang Q, Meyer MD, Anderson DJ, Campbell JE, Carroll PJ. Synthesis of 5- and 6-(6-chloro-3-pyridyl)-2-azabicyclo[2.2.0]hexanes. Epibatidine analogs. Tetrahedron 2000;56:9233-9239.
89. Cox CD, Malpass JR, Gordon J, Rosen A. Synthesis of epibatidine isomers: Endo-5- and 6-(6′-chloro-3′-pyridyl-2-azabicyclo[2.2.1]heptanes. J Chem Soc Perkin Trans 1 2001;2372-2379.
90. Dart MJ, Wasicak JT, Ryther KB, Schrimpf MR, Kim KH, Anderson DJ, Sullivan JP, Meyer MD. Structural aspects of high affinity ligands for the α4β2 neuronal nicotinic receptor. Pharm Acta Helv 2000;74:115-123.
91. Hodgson DM, Maxwell CR, Wisedale R, Matthew IR, Carpenter KJ, Dickenson AH, Wonnacott S. 6-Substituted 2-azabicyclo[2.2.1]hept-5-enes by nitrogen-directed radical rearrangement: Synthesis of an epibatidine analogue with high binding affinity at the nicotinic acetylcholine receptor. J Chem Soc Perkin Trans 1 2001;3150-3158.
92. Bai D, Xu R, Chu G, Zhu X. Synthesis of (±)-epibatidine and its analogues. J Org Chem 1996;61:4600-4606.
93. Kim Y-H, Oh C-Y, Lee K-Y, Lee Y-S, Jung Y-H, Park H-J, Ham W-H. Synthesis of (±)-homoepibatidine analogues. Arch Pharm Res 2002;25:49-52.
94. Malpass JR, Hemmings DA, Wallis AL, Fletcher SR, Patel S. Synthesis and nicotine acetylcholine-binding properties of epibatidine homologues: Homoepibatidine and dihomoepibatidine. J Chem Soc Perkin Trans 1 2001;1044-1050.
95. Zhang C, Gyermek L, Trudell ML. Synthesis of optically pure epibatidine analogs: (1R, 2R, 5S)-2β-(2-chloro-5-pyridinyl)-8-azabicyclo[3.2.1]octane and (1R, 2S, 5S)-2α-(2-chloro-5-pyridinyl)-8-azabicy-clo[3.2.1]octane from (-)-cocaine. Tetrahedron Lett 1997;38:5619-5622.
96. Gündisch D, Harms K, Schwarz S, Seitz G, Stubbs MT, Wegge T. Synthesis and evaluation of diazine containing bioisosteres of (-)-ferruginine as ligands for nicotinic acetylcholine receptors. Bioorg Med Chem 2001;9:2683-2691.
97. Wright E, Gallagher T, Sharples CGV, Wonnacott S. Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/epibatidine hybrid. Bioorg Med Chem Lett 1997;7:2867-2870.
98. Sharples CGV, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, Wonnacott S. UB-165: A novel nicotinic agonist with subtype selectivity implicates the α4β2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 2000;20:2783-2791.
99. Gohlke H, Gündisch D, Schwarz S, Seitz G, Tilotta MC, Wegge T. Synthesis and nicotinic binding studies on enatiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene UB165. J Med Chem 2002;45:1064-1072.
100. Gündisch D, Kämpchen T, Schwarz S, Seitz G, Siegl J, Wegge T. Syntheses and evaluation of pyridazine and pyrimidine containing bioisosteres of (±)-pyrido[3,4-b]homotropane and pyrido[3,4-b]tropane as novel nAChR ligands. Bioorg Med Chem 2002;10:1-9.
101. Papke RL, Heinemann SF. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol Pharmacol 1994;45:142-149.
102. Canu Boido C, Sparatore F. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Il Farmaco 1999;54:438-451.
103. Houlihan LM, Slater Y, Guerra DL, Peng J-H, Kuo Y-P, Lukas RJ, Cassels BK, Bermudez I. Activity of cytisine and its brominated isosteres on recombinant human α7, α4β2, and α4β4 nicotinic acetylcholine receptors. J Neurochem 2001;78:1029-1043.
104. Ward JS, Merritt L, Bymaster FP, Calligaro DO. Isoarecolones and arecolones: Selective central nicotinic agonists that cross the blood-brain barrier. Bioorg Med Chem Lett 1994;4:573-578.
105. Ghelardini C, Galeotti N, Gualtieri F, Bellucci C, Manetti D, Borea PA, Bartolini A. Antinociceptive property of the nicotinic agonist AG-4 in rodents. Drug Dev Res 1997;41:1-9.
106. Guandalini L, Dei S, Gualtieri F, Romanelli MN, Scapecchi S, Teodori E, Varani K. Synthesis of hexahydro-2-pyrindine (= hexahydrocyclopenta[c]pyridine) derivatives as conformationally restricted analogs of the nicotinic ligands arecolone and isoarecolone. Helv Chim Acta 2002;85:96-107.
107. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, Mack R, Loch J, Wu E, Kover A, Verhoest P, Sampognaro A, Phillips E, Zhu Y, Murray R, Griffith R, Blosser J, Gurley D, Machulskis A, Zongrone J, Rosen A, Gordon J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. J Med Chem 2000;43:4045-4050.
108. Badio B, Shi D, Garraffo HM, Daly JW. Antinociceptive effects of the alkaloid epibatidine: Further studies on involvement of nicotinic receptors. Drug Dev Res 1995;36:46-59.
109. Terry AV, Williamson R, Gattu M, Beach JW, McCurdy CR, Sparks JA, Pauly JR. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology 1998;37:93-102.
110. Flammia D, Dukat M, Damaj MI, Martin B, Glennon RA. Lobeline: Structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem 1999;42:3726-3731.
111. Tønder JE, Hansen JB, Begtrup M, Pettersson I, Rimvall K, Christensen B, Ehrbar U, Olesen PH. Improving the nicotinic pharmacophore with a series of (isoxazole)methylene-1-azacyclic compounds: Synthesis, structure-activity relationship, and molecular modeling. J Med Chem 1999;42:4970-4980.
112. Olesen PH, Tønder JE, Hansen JB, Hansen HC, Rimvall K. Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors. Bioorg Med Chem 2000;8:1443-1450.
113. Choi KI, Cha JH, Cho YS, Pae AN, Jin C, Yook J, Cheon HG, Jeong D, Kong JY, Koh HY. Binding affinities of 3-(3-phenylisoxazol-5-yl)methylidene-1-azabicycles to acetylcholine receptors. Bioorg Med Chem Lett 1999;9:2795-2800.
114. 4-phenylpiperazinium iodide (DMPP). J Med Chem 2001;44:3946-3955.
115. 4-dimethyl-piperazinium iodide (DMPP) with central nicotinic action. Bioorg Med Chem 1999;7:457-465.
116. Nielsen SF, Nielsen EO, Olsen GM, Liljefors T, Peters D. Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis. J Med Chem 2000;43:2217-2226.
117. Vernier J-M, El-Abdellaoui H, Holsenback H, Cosford NDP, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, Reid R, Sacaan AI, Suto C, Washburn M, Lloyd GK, McDonald IA. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl] thio]phenol hydrochloride (SIB-1553A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 1999;42:1684-1686.
118. Efange SMN, Tu Z, von Hohenberg K, Francesconi L, Howell RC, Rampersad MV, Todaro LJ, Papke RL, Kung M-P. 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: Synthesis and preliminary pharmacological characterization. J Med Chem 2001;44:4704-4715.
119. 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 2001;11:319-321.
120. Hardick DJ, Cooper G, Scott-Ward T, Blagbrough IS, Potter BVL, Wonnacott S. Conversion of the sodium channel activator aconitine into a potent α7-selective nicotinic ligand. FEBS Lett 1995;365:79-82.
121. Hardick DJ, Blagbrough IA, Cooper G, Potter BVL, Critchley T, Wonnacott S. Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal α-bungarotoxin binding sites: Importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding. J Med Chem 1996;39:4860-4866.
122. Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Wonnacott S. Structure-activity studies of bicyclic and tricyclic analogues of methyllycaconitine. Biochem Soc Trans 1997;25:545S.
123. Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, McKay SB, Bergmeier SC, McKay DB. Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal α3β4* nicotine receptors. Neurosci Res 2002;42:57-63.
124. Matsuda K, Buckingham SD, Kleier D, Rauh JJ, Grauso M, Sattelle DB. Neonicotinoids. Trends Pharmacol Sci 2001;22:573-580.
125. Tomizawa M, Lee DL, Casida JE. Neonicotinoid insecticides: Molecular features conferring selectivity for insect versus mammalian nicotinic receptors. J Agric Food Chem 2000;48:6016-6024.
126. Zhang N, Tomizawa M, Casida JE. Structural features of azidopyridinyl neonicotinoid probes conferring high affinity and selectivity for mammalian α4β2 and Drosophila nicotinic receptors. J Med Chem 2002;45:2832-2840.
127. Beers WH, Reich E. Structure and activity of acetylcholine. Nature 1970;228:917-922.
128. Palmer RA, Tickle JH, Tickle IJ. Acetylcholine receptor site: A proposed model. J Mol Graph 1983;1:94-106.
129. Sheridan RP, Nilakantan R, Dixon JS, Venkataraghavan R. The ensemble approach to distance geometry: Application to the nicotinic pharmacophore. J Med Chem 1986;29:899-906.
130. Behling RW, Yamane T, Navon G, Jelinski LW. Conformation of acetylcholine bound to the nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1988;85:6721-6725.
131. Gund TM, Spivak CE. Pharmacophore for nicotinic agonists. Methods Enzymol 1991;203:677-693.
132. Glennon RA, Herndon JL, Dukat M. Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med Chem Res 1994;4:461-473.
133. Fraenkel Y, Shalev DE, Gershoni JM, Navon G. Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: The cholinergic system - A model. Crit Rev Biochem Mol Biol 1996;31:273-301.
134. Cheng YX, Dukat M, Dowd M, Fiedler W, Martin B, Damaj MI, Glennon RA. Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-D]azepine and related ring-opened analogs at central nicotinic receptors. Eur J Med Chem 1999;34:177-190.
135. Kim KH, Lin N-H, Anderson DJ. Quantitative structure-activity relationships of nicotine analogues as neuronal nicotinic acetylcholine receptor ligands. Bioorg Med Chem 1996;12:2211-2217.
136. Dukat M, Dowd M, Damaj MI, Martin B, El-Zahabi MA, Glennon RA. Synthesis, receptor binding and QSAR studies on 6-substituted nicotine derivatives as cholinergic ligands. Eur J Med Chem 1999;34:31-40.
137. Nicolotti O, Canu Boido C, Sparatore F, Carotti A. Cytisine derivatives as high affinity nAChR ligands: Synthesis and comparative molecular field analysis. Il Farmaco 2002;57:469-478.
138. Manallack DT, Gallagher T, Livingstone DJ. Quantitative structure-activity relationships of nicotinic agonists. In: Devillers J, editor. Neural networks in QSAR and drug design. France: Rillieux la Pape. 1996. pp 177-208.
139. 3H]-N-methylcarbamylcholine. J Comput-Aid Mol Des 2001;15:247-258.
140. Nicolotti O, Pellegrini-Calace M, Carrieri A, Altomare C, Centeno NB, Sanz F, Carotti A. Neuronal nicotinic receptor agonists: A multi-approach development of the pharmacophore. J Comput-Aid Mol Des 2001;15:859-872.
141. Nicolotti O, Pellegrini-Calace M, Altomare C, Carotti A, Carrieri A, Sanz F. Ligands of neuronal nicotinic acetylcholine receptor (nAChR): Inferences from the Hansch and 3-D quantitative structure-activity relationship (QSAR) models. Curr Med Chem 2002;9:1-29.
142. Rajendra S, Vandenberg RJ, Pierce KD, Cunningham AM, French PW, Barry PH, Schofield PR. The unique extracellular disulfide loop of the glycine receptor is a principal ligand binding element. EMBO J 1995;14:2987-2998.
143. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 1991;253:872-879.
144. Smit AB, Syed NI, Schaap D, van Minnen J, Klumperman J, Kits KS, Lodder H, van der Schors RC, van Elk R, Sorgedrager B, Brejc K, Sixma TK, Geraerts WPM. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 2001;411:261-268.
145. Dougherty DA, Stauffer DA. Acetylcholine binding by a synthetic receptor: Implications for biological recognition. Science 1990;250:1558-1560.
146. Dougherty DA. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr and Trp. Science 1996;271:163-168.
147. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA. From ab initio quantum mechanics to molecular neurobiology: A cation-π binding site in the nicotinic receptor. Proc Natl Acad Sci USA 1998;95:12088-12093.
148. Schmitt JD, Sharples CGV, Caldwell WS. Molecular recognition in nicotinic acetylcholine receptors: The importance of π-cation interactions. J Med Chem 1999;42:3066-3074.
149. Guy HR. Structural models of the nicotinic acetylcholine receptor and its toxin-binding sites. Cell Mol Neurobiol 1981;1:231-258.
150. Luyten WHML. A model for the acetylcholine binding site of the nicotinic acetylcholine receptor. J Neurosci Res 1986;16:51-73.
151. Aprison MH, Galvez-Ruano E, Lipkowitz KB. The nicotinic cholinergic receptor: A theoretical model. J Neurosci Res 1996;46:226-230.
152. Bhat AA, Taylor EW. Structural evaluation of distant homology. A 3-D model of the ligand binding domain of the nicotinic acetylcholine receptor based on acetylcholinesterase: Consistency with experimental data. J Mol Modeling 1996;2:46-50.
153. Tsigelny I, Sugiyama N, Sine SM, Taylor P. A model of the nicotinic receptor extracellular domain based on sequence identity and residue location. Biophys J 1997;73:52-66.
154. Schapira M, Abagyan R, Totrov M. Structural model of nicotine acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Struct Biol 2002;2:1-8.
155. 2+-binding sites. Proc Natl Acad Sci USA 2002;99:3210-3215.
156. Fruchart-Gaillard C, Gilquin B, Antil-Delbeke S, Le Novère N, Tamiya T, Corringer P-J, Changeux J-P, Menez A, Servent D. Experimentally based model of a complex between a snake toxin and the α7 nicotinic receptor. Proc Natl Acad Sci USA 2002;99:3216-3221.
157. Le Novère N, Changeux J-P. LGICdb: The ligand-gated ion channel database. Nucleic Acids Res 2001;29:294-295.
158. Paradiso K, Sabey K, Evers AS, Zorumski CF, Covey DF, Steinbach JH.
159. Galzi JL, Bertrand S, Corringer P-J, Changeux J-P, Bertrand D. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic receptor. EMBO J 1996;15:5824-5832.
160. Buisson B, Bertrand D. Allosteric modulation of neuronal nicotinic acetylcholine receptors. J Physiol 1998;92:89-100.
161. 2+ in rat chromaffin cells in vitro. J Neurosci 1999;19:2945-2953.
162. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, Heintz N. Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 1999;23:105-114.
163. Ibanez-Tallon I, Miwa JM, Wang H-L, Adams NC, Crabtree GW, Sine SM, Heintz N. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. Neuron 2002;33:893-903.
164. Maelicke A, Schrattenholz A, Schröder H. Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. Semin Neurosci 1995;7:103-114.
165. Schrattenholz A, Godovac-Zimmermann J, Schäfer HJ, Albuquerque EX, Maelicke A. Photoaffinity labelling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem 1993;216:671-677.
166. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M. Allosteric sensitization of nicotinic receptors by galanthamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001;49:279-288.
167. Albuquerque EX, Pereia EF, Alkondon M, Schrattenholz A, Maelicke A. Nicotinic aceylcholine receptors on hippocampal neuron: Distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res 1997;17:243-266.
168. Krause RM, Buisson B, Bertrand S, Corringer P-J, Galzi J-L, Changeux J-P, Bertrand D. Ivermectin: A positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283-294.
169. Curtis L, Buisson B, Bertrand S, Bertrand D. Potentiation of human α4β2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 2002;61:127-135.
170. Francis MM, Cheng EY, Weiland GA, Oswald RE. Specific activation of the α7 nicotinic acetylcholine receptor by a quaternary analog of cocaine. Mol Pharmacol 2001;60:71-79.
171. Di Angelantonio S, Costa V, Carloni P, Messori L, Nistri A. A novel class of peptides with facilitating action on neuronal nicotinic receptors of rat chromaffin cells in vitro: Functional and molecular dynamics studies. Mol Pharmacol 2002;61:43-54.
172. Arias HR. Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1998;1376:173-220.
173. Arias HR. Role of local anesthetics on both cholinergic and serotonergic ionotropic receptors. Neurosci Biobehav Rev 1999;23:817-843.
174. Arias HR, Mccardy E, Gallagher MJ, Blanton MP. Interaction of barbiturate analogs with the Torpedo californica nicotinic acetylcholine receptor ion channel. Mol Pharmacol 2001;60:497-506.
175. Xiao Y, Smith RD, Caruso FS, Kellar KJ. Blockade of rat α3β4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther 2001;299:366-371.
176. Oka K, Andoh T, Watanabe I, Kamiya Y, Ito H. Inhibition of the neuronal nicotinic receptor-mediated current by kappa opioid receptor agonists in PC12 cells. Pflügers Arch-Eur J Physiol 1998;436:887-893.
177. Mahata M, Mahapatra NR, O'Connor DT, Mahata SK. Chromaffin cell catecholamine secretion: Bisindolylmaleimide compounds exhibit novel and potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. Mol Pharmacol 2002;61:1340-1347.
178. Park T-J, Seo H-K, Kang B-J, Kim K-T. Noncompetitive inhibition by camphor of nicotinic acetylcholine receptors. Biochem Pharmacol 2001;61:787-793.
179. Tomé AR, Izaguirre V, Rosario LM, Ceña V, Gonzales-Garcia C. Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells. Brain Res 2001;903:62-65.
180. Nguyen Q-T, Miledi R. Inhibition of skeletal muscle nicotinic receptors by the atypical antipsychotic clozapine. Neuropharmacology 2002;42:662-669.
181. Löwenick CV, Kramplf K, Schneck H, Kochs E, Bufler J. Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur J Pharmacol 2001;413:31-35.
182. Steinbach JH, Chen Q. Antagonist and partial agonist actions of d-tubocurarine at mammalian muscle acetylcholine receptors. J Neurosci 1995;15:230-240.
183. Coates KM, Mather LE, Johnson R, Flood P. Thiopental is a competitive inhibitor at the human α7 nicotinic acetylcoline receptor. Anesth Analg 2001;92:930-933.
184. Arias HR. Agonist self-inhibitory binding site on the nicotinic acetylcholine receptor. J Neurosci Res 1996;44:97-105.
185. Rayes D, De Rosa MJ, Spitzmaul G, Bouzat C. The anthelmintic pyrantel acts as a low efficacious agonist and an open-channel blocker of mammalian acetylcholine receptors. Neuropharmacology 2001;41:238-245.
186. Fucile S, Palma E, Eusebi F, Miledi R. Serotonin antagonizes the human neuronal α7 nicotinic acetylcholine receptor and becomes an agonist after L248T α7 mutation. Neurosci 2002;110:169-179.
187. Demuro A, Palma E, Eusebi F, Miledi R. Inhibition of nicotinic actylcholine receptors by bicuculline. Neuropharmacology 2001;41:854-861.
188. Usherwood PNR. Natural and synthetic polyamines: Modulators of signalling proteins. Il Farmaco 2000;55:202-205.
189. Strømgaard K, Andersen K, Krogsgaard-Larsen P, Jaroszewski J. Recent advances in the medicinal chemistry of polyamine toxins. Mini Rev Med Chem 2001;1:317-338.
190. Strømgaard K, Brierley MJ, Andersen K, Sløk FA, Mellor IR, Usherwood PNR, Krogsgaard-Larsen P, Jaroszewski JW. Analogues of neuroactive polyamine wasp toxins that lack inner basic sites exhibit enhanced antagonism toward a muscle-type mammalian nicotinic acetylcholine receptor. J Med Chem 1999;42:5224-5234.
191. Strømgaard K, Mellor IR, Andersen K, Neagoe I, Pluteanu F, Usherwood PNR, Krogsgaard-Larsen P, Jaroszewski JW. Solid-phase synthesis and pharmacological evaluation of analogues of PhTX-12 - A potent and selective nicotinic acetylcholine receptor antagonist. Bioorg Med Chem Lett 2002;12:1159-1162.
192. Rosini M, Budriesi R, G BM, Bolognesi ML, Chiarini A, Hucho F, Krogsgaard-Larsen P, Mellor IR, Minarini A, Tumiatti V, Usherwood PNR, Melchiorre C. Design, synthesis and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. J Med Chem 1999;42:5212-5223.
193. Rosini M, G BM, Marucci G, Budriesi R, Krauss M, Bolognesi ML, Minarini A, Tumiatti V, Hucho F, Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. J Med Chem 2002;45:1860-1878.
194. Bolognesi ML, G BM, Marucci G, Bartolini M, Krauss M, Angeli P, Antonello A, Rosini M, Tumiatti V, Hucho F, Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetramine backbone into a macrocyclic structure. J Med Chem 2002;45:3286-3295.
195. Romano C, Goldstein A. Stereospecific nicotine receptors on rat brain membranes. Science 1980;210:647-650.
196. 3H-labeled azetidine analogue of nicotine. Biochem Pharmacol 1987;36:2337-2341.
197. 3H]ABT-418: A novel cholinergic channel ligand. J Pharmacol Exp Ther 1995;273:1434-1441.
198. 125I]iodo-MLA). A new ligand for the α7 nicotinic acetylcholine receptor. J Med Chem 2000;43:142-145.
199. Mogg AJ, Whiteaker P, McIntosh JM, Marks MJ, Collins AC, Wonnacott S. Mehyllycaconitine is a potent antagonist of α-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 2002;302:197-204.
200. 3H]methylcarba-mylcholine in rat brain. Eur J Pharmacol 1994;253:261-267.
201. Vailati S, Hanke W, Bejan A, Barabino B, Longhi R, Balestra B, Moretti M, Clementi F, Gotti C. Functional α6-containing nicotinic receptors are present in chick retina. Mol Pharmacol 1999;56:11-19.
202. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: Topography and pathology. J Chem Neuroanat 2000;20:281-298.
203. Seguela P, Wadiche J, Dinely-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties and distribution of rat brain α7: A nicotinic channel highly permeable to calcium. J Neurosci 1993;13:596-604.
204. 3H]-methyllycaconitine in the mouse brain. Eur J Neurosci 1999;11:2689-2696.
205. 3H] Epibatidine labels nicotinic receptors in rat brain: An autoradiographic study. J Pharmacol Exp Ther 1995;275:1030-1034.
206. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol 1995;48:280-287.
207. Marks MJ, Smith KW, Collins AC. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. J Pharmacol Exp Ther 1998;285:377-386.
208. 125I-α-Conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol Pharmacol 2000;57:913-925.
209. Whiteaker P, Peterson CG, Xu W, Mcintosh JM, Paylor R, Beaudet AL, Collins AC, Marks MJ. Involvement of the α3 subunit in central nicotinic binding populations. J Neurosci 2002;22:2522-2529.
210. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J Pharmacol Exp Ther 1997;282:445-451.
211. 125I]-epibatidine. Br J Pharmacol 2000;131:729-739.
212. Sihver W, Nordberg A, Långström B, Mukhin AG, Koren AO, Kimes AS, London ED. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res 2000;113:143-157.
213. Gündisch D. Nicotinic acetylcholine receptors and imaging. Curr Pharm Des 2000;6:1143-1157.
214. 125/123I] 5-Iodo-3-pyridyl ethers: Syntheses and binding to neuronal nicotinic acetylcholine receptors. Nucl Med Biol 2001;28:911-921.
215. 11C]methyl-2-(S)- pyrrolidinylmethoxy)pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. Bioorg Med Chem 2001;9:3055-3058.
216. Goodman A, Gilman A. The Pharmacological Basis of Therapeutics. IXth edition. New York: McGrow-Hill; 1996.
217. Mihailescu S, Drucker-Colìn R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Medical Res 2000;31:131-144.
218. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, Iversen P, Bauman M, Perry E. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002;125:1483-1495.
219. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166-174.
220. Jones MV, Westbrook GL. The impact of receptor desensitization on fast synaptic transmission. Trends Neurosci 1996;19:96-101.
221. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996;16:905-908.
222. Chiodini FC, Tassonyi E, Hulo S, Bertrand D, Muller D. Modulation of synaptic transmission by nicotine and nicotinic antagonists in hippocampus. Brain Res Bull 1999;48:623-628.
223. Dwoskin LP, Crooks PA. Competitive neuronal nicotinic receptor antagonists: A new direction for drug discovery. J Pharmacol Exp Ther 2001;298:395-402.
224. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behav Brain Res 2000;113:117-120.
225. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992;108:485-494.
226. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. Intravenous nicotine in Alheimer's disease: A pilot study. Psychopharmacology 1988;95:171-175.
227. Newhouse PA, Potter A, Levin ED. Nicotinic systems involvement in Alzheimer's and Parkinson's diseases: Implication for therapeutics. Drugs Aging 1997;11:206-228.
228. Brazell MP, Mitchell SN, Gray JA. Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: A dose-response and antagonist study. Neuropharmacology 1991;30:823-833.
229. Brazell MP, Mitchell SN, Joseph MH, Gray JA. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: Comparison with caudate-putamen. Neuropharmacology 1990;29:1177-1185.
230. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biol Psychiatry 2001;49:200-210.
231. Sugaya K, Giacobini E, Chiappinelli VA. Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease. J Neurosci Res 1990;27:349-359.
232. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving A, Brown A, Perry RH. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neurosci 1995;64:385-395.
233. Hellström-Lindhal E. Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 2000;393:255-263.
234. 1-42 binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 2000;75:1155-1161.
235. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001;21:RC120, 1-5.
236. Dineley KT, Bell KA, Bui D, Sweatt JD. β-Amyloid peptide activates α7 nicotinic receptors expressed in Xenopus oocytes. J Biol Chem 2002;277:25056-25061.
237. Baron JA. Cigarette smoking and Parkinson's disease. Neurology 1986;36:1490-1496.
238. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 1994;116:117-119.
239. Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M. Stimulation of nigrostriatal dopamine neurons by nicotine. Neuropharmacology 1982;21:963-968.
240. Mihailescu S, Palomero-Rivero M, Meade-Huerta P, Maza-Flores A, Drucker-Colin R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol 1998;360:31-36.
241. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 2000;393:223-230.
242. Sorenson EM, Shiroyama T, Kitai ST. Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat. Neuroscience 1998;87:659-673.
243. Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK. Pharmacological characterization of SIB-1765F, a novel cholinergic ion channel agonist. J Pharmacol Exp Ther 1997;280:373-383.
244. Le Novère N, Zoli M, Changeux J-P. Neuronal nicotinic receptor alpha6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 1996;8:2428-2439.
245. Williams M, Kowaluk EA, Arneric SP. Emerging molecular approaches to pain therapy. J Med Chem 1999;42:1481-1500.
246. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 2001;10:1819-1830.
247. Davis L, Pollock LJ, Stone T. Visceral pain. Surg Gynecol Obstet 1932;55:418-426.
248. Badio B, Daly JW. Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 1994;45:563-569.
249. Daly JW, Garraffo HM, Spande TF, Decker MW, Sullivan JP, Williams M. Alkaloids from frog skin: The discovery of epibatidine and the potential for developing novel non-opioid analgesics. Natl Prod Rep 2000;17:131-135.
250. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux J-P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999;398:805-810.
251. Weiland S, Bertrand D, Leonard S. Neuronal nicotinic acetylcholine receptors: From the gene to the disease. Behav Brain Res 2000;113:43-56.
252. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Sheffer IE, Berkovic SF. A missense mutation in the neuronal acetylcholine nicotinic receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-203.
253. Steinlein OK, Magnusson A, Stoodt J, Bertrand S, Weiland S, Berkovic SF, Nakken KO, Propping P, Bertrand D. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 1997;6:943-947.
254. Buisson B, Curtis L, Bertrand D. Neuronal nicotinic acetylcholine receptor and epilepsy. In: Berkovic SF, Genton P, Hirsch E, Picard F, editors. Genetics of focal epilepsy: Clinical aspects and molecular biology. John Libbey & Co.; 1999. pp 187-202.
255. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992;8:93-102.
256. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33.
257. Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr Res 1994;12:131-136.
258. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-1194.
259. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995;7:373-378.
260. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck DH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorders. Psychopharmacology 1996;123:55-63.
261. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 1989;79:157-163.
262. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 1997;74:21-25.
263. Sanberg PR, Shytle RD, Silver AA. Treatment of Tourette's syndrome with mecamylamine. Lancet 1998;352:705-706.
264. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994;16:36-44.
265. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2000; CD000124.
266. Haustein KO. Pharmacotherapy of nicotine dipendence. Int J Clin Pharmacol Ther 2000;38:273-290.
267. Rose JE. Nicotine addition and treatment. Ann Rev Med 1996;47:493-507.
268. Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002;63:89-98.
269. Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 2002;438:99-105.
270. 3H]N-methyl-carbamylcholine, a new radioligand specific for nicotinic acetylcholine receptors in brain. Eur J Pharmacol 1987;139:323-333.
271. 3H]methylcarbamylcholine, a novel radioligand. Life Sci 1987;41:2851-2861.
272. 3H]methylcharbamylcholine, a new radioligand for studying nicotinic receptors. Biochem Pharmacol 1986;35:4199-4222.
273. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 1991;39:9-12.
274. Lukasiewicz RJ, Bennett EL. alpha-bungarotoxin binding properties of a central nervous system nicotinic acetylcholine receptor. Biochim Biophys Acta 1978;544:294-308.
275. Gopalakrishnan M, Buisson B, Touma E, Giordano T, Campbell JE, Hu IC, Donnelly-Roberts D, Arneric SP, Bertrand D, Sullivan JP. Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor. Eur J Pharmacol 1995;290:237-246.
276. 3H]methyllycaconitine: A new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 1999;38:679-690.
277. 3H]acetylcholine binding sites. J Pharmacol Exp Ther 1990;253:51-57.
278. 76Br]bromo-3-[[2(S)-azetidinyl] methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J Neurochem 1999;73:1264-1272.
279. Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ. Rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: Pharmacology of ligand binding and function. Mol Pharmacol 1998;54:322-333.
280. Zhang X, Gong Z-H, Fasth KJ, Långström B, Nordberg A. Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. Neurochem Int 1998;32:435-441.
281. 3H]Epibatidine binding to bovine adrenal medulla: Evidence for α3β4* nicotinic receptors. Neurosci Lett 2002;318:98-102.